A total of @ patients with intermediate - or high-risk Ta T@ ( without carcinoma in situ ) NMIBC were randomized in European Organization for Research and Treatment of Cancer ( EORTC ) trial @ comparing six weekly instillations of epirubicin , BCG , and BCG plus isoniazid followed by three weekly maintenance instillations over @ yr .